8
Apr
2025
We Need an mRNA Champion in a Red Cape
I grew up in an era of Superman comic books. Superman captivated the imagination of a generation of kids like me. It told stories of an otherwise ordinary human who could achieve extraordinary feats of speed and strength, leaping tall buildings with a single bound, to defeat the bad guys. Miracles could happen on a foundation of truth and justice,... Read More
7
Apr
2025
Leaving A Mark On Patients
Leading a nonprofit that helps kids and families with terrible diseases requires a certain ability to roll with the punches. That feeling hit last week when I heard about Peter Marks’ forced resignation as Director of the FDA’s Center for Biologics Evaluation and Research (CBER). Here was a scientific champion of innovative cell and gene therapies at the FDA. He... Read More
6
Apr
2025
Meet the Timmerman Traverse for Life Science Cares 2025 Team
The 5th annual Timmerman Traverse for Life Science Cares is fired up and ready for outdoor adventure in 2025. We’re on a mission to raise $1 million to fight poverty. This year’s team is preparing for a pair of challenging hikes in the Pacific Northwest, Aug. 18-19. We’ll cover 20 miles of trails, ascend 7,000 vertical feet, and savor some... Read More
3
Apr
2025
FDA Gutted, Novartis Kidney Drug Pays Off, and Isomorphic Raises a Fortune
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
Apr
2025
Timmerman Traverse for Damon Runyon Hits $700K Goal, Fueling Cancer Research
Times are tough in biotech, but this is an industry where we learn, adapt, and move forward. I’m proud to announce that the 2025 Timmerman Traverse for Damon Runyon Cancer Research Foundation has hit its fundraising goal of $700,000 to support high-risk / high-reward cancer research. We stand at $702,555 in closed donations. Our team of 16 hikers is now... Read More
31
Mar
2025
Relationships That Make TechBio Go ‘Round: David Roblin on The Long Run
David Roblin is today’s guest on The Long Run podcast. David is the CEO of London-based Relation Therapeutics. The company uses multi-omic tools to look for drug targets in human tissue samples. It seeks to find the relationships between perturbed biological states and disease, with the help of machine learning. Relation emphasizes relationships in another sense as well – the... Read More
30
Mar
2025
Looking Back and Seeing The Future: The Relationships that Propel Biotech
It’s been a rough week (again) for those of us within the biotech ecosystem. Actually, it’s been a rough month. Hell, let’s just say it’s been a hard year. Or two. Rather than writing about the negatives – there will be plenty of time for that, I suspect – I’d like to share a delightful little story. I recently returned... Read More
29
Mar
2025
GLP-1s Secret Weapon: Improving Health By Enhancing Agency
The arrival of generative AI prompted many to worry about the adverse impact on human agency; after all, if the technology can effectively do what we’re doing, where does that leave us? This concern was the central focus of Reid Hoffman’s “Superagency,” which I reviewed for the WSJ earlier this year – see here. Essentially, Hoffman argues that new technologies... Read More
28
Mar
2025
Longevity Is Having A Moment
Dying, with few exceptions, has never been especially popular, and our shared interest in not dying hardly constitutes breaking news. Nevertheless, the aspiration of living longer — and remaining healthier while doing it — appears to be all the rage. Consider these recent headlines: “Why is longevity sudden so hot?” – Chrissy Farr, Second Opinion. “The longevity business is booming... Read More
27
Mar
2025
A Moment of Peril and Promise
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Mar
2025
NIH Cuts Threaten to Cede U.S. Life Science Dominance to China
The current debate over capping federal research overhead rates misses the forest for the trees. Federal investments in medical research have built a thriving U.S. biotech sector that employs 2.3 million people. Funding from the National Institutes of Health (NIH) provides the foundation for this success, supporting universities and research institutions that attract top scientists and foster innovation. The Trump... Read More
23
Mar
2025
How a Dark Horse Candidate is Upending the Sequencing Market
Before Roche officially announced their new sequencer in a pre-AGBT webinar in February 2025, only true sequencing aficionados had heard of Stratos Genomics or Sequencing by Expansion (SBX). The SBX chemistry underlying Roche’s new sequencer was developed by Stratos Genomics, which Roche acquired in 2020 and paired with nanopore sensors from Genia Technologies, which Roche acquired way back in 2014.... Read More
20
Mar
2025
Curevo and Arbor Defy Gravity, Cargo Hits the Wall, & AZ Bets on In Vivo
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
18
Mar
2025
See the Photos from TR10 West
Thanks to everyone who attended the TR10 anniversary party Mar. 13 at Adaptive Biotechnologies. The toasts and roasts were funny, perceptive and heartfelt. It was a joyous occasion. Enjoy a few photos. Click to enlarge. Photos by Robert Wade.
18
Mar
2025
See the Photos from TR10 East
Thanks to everyone who attended the TR10 anniversary party Mar. 6 at Alnylam Pharmaceuticals. The toasts and roasts were funny, perceptive and heartfelt. There was a joyful community spirit in the room. Enjoy a few photos. Click to enlarge. Photos by Mike Mejia.
18
Mar
2025
Arbor Survives Winter, Gets $73.9M to Take Gene Editing to the Clinic
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
Mar
2025
Why Cell & Gene Therapy Companies Should Talk with RFK Jr.
As the CEO of the cell and gene therapy advocacy organization the Alliance for Regenerative Medicine (ARM), I’ve been asked one question more than any other amid the constant barrage of news headlines the past two months. How are you approaching the Trump Administration? I hear it from across our community, including biotechnology companies, academic and medical research institutions, patient... Read More
17
Mar
2025
CAR-T cell Therapies Made In the Body: Andy Scharenberg on The Long Run
Andy Scharenberg is today’s guest on The Long Run. Andy is the co-founder and CEO of Seattle-based Umoja Biopharma. The company is developing in vivo CAR-T cell therapies. The idea is to use gene therapy, delivered in a single shot, that can reprogram T cells of the immune system to recognize markers on cancer cells and then hunt down cancer... Read More
17
Mar
2025
Curevo Captures $110M to Develop a More Tolerable Shingles Vaccine
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Mar
2025
Protagonist Delivers, BMS Bargain Hunts, and Zealand Goes Major League
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.